JPMorgan Adjusts Price Target on IQVIA Holdings to $295 From $285

Stifel raised its price target for IQVIA (NYSE:IQV) to $303 from $276, citing an improving market backdrop and strong company performance. The stock is near its 52-week high and has surged 48.72% over the past six months. Multiple analysts have raised their price targets and maintained buy ratings, highlighting IQVIA's growth prospects and strong data infrastructure.

UBS raised its price target for IQVIA from $240 to $345, maintaining a buy rating. The company's stock is currently trading at $270.77. RBC Capital Markets also noted a positive outlook for IQVIA due to accelerating drug approvals.

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.

IQVIA Holdings plans to raise $2 billion via senior notes due 2034, with a 6.375% interest rate. Proceeds will redeem existing notes, repay credit facility debt, and cover expenses. The offering is expected to close by September 23, 2026, pending market conditions.

IQVIA Holdings (IQV) has outperformed Agilent Technologies (A) in the diagnostics and research sector, with a 6.4% YTD gain and 14.7% increase over 52 weeks. Analysts give IQV a 'Strong Buy' rating, with a mean price target of $277.16, implying 7.9% upside.